Apixaban: an Oral Direct Factor-Xa Inhibitor

The Role of Apixaban for Venous and Arterial Thromboembolic Disease

(2011) Rathasen Prom et al.   ANNALS OF PHARMACOTHERAPY

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

(2011) Kan He et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

(2011) Richard C. Becker et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial

(2011) Drahomir Aujesky et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

(2011) Samuel Z. Goldhaber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

(2011) John H. Alexander et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outpatient management of acute deep vein thrombosis: Results from the OTIS-DVT registry

(2011) David Spirk et al.   THROMBOSIS RESEARCH

Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism

(2010) David Jiménez   ARCHIVES OF INTERNAL MEDICINE

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin

(2010) Xiaosui Jiang et al.   THROMBOSIS AND HAEMOSTASIS

Apixaban versus enoxaparin in patients with total knee arthroplasty

(2010) Jiahao Huang et al.   THROMBOSIS AND HAEMOSTASIS

Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect

(2010) Esther R. van Bladel et al.   THROMBOSIS RESEARCH

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

(2009)   CIRCULATION

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

(2009) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement

(2009) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Parenteral Anticoagulants

(2008) Jack Hirsh et al.   CHEST

Antithrombotic and Thrombolytic Therapy

(2008) Jack Hirsh et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Prevention of Venous Thromboembolism

(2008) William H. Geerts et al.   CHEST

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS